



# Shewanella algae Infection in United States Naval Special Warfare Trainees

Kristi K. Stone-Garza, MD, MPH <sup>1</sup>, Paul C.F. Graf, PhD, D(ABMM) <sup>2</sup>, Daniel Croom, MD <sup>3</sup>, Mari Brown, MPH, MS <sup>4</sup>, Cheryl H. Andreoli, PhD <sup>4</sup>, Peter Woodson, MD <sup>3</sup>, Ryan C. Maves, MD<sup>1,5</sup>

(1) Division of Infectious Diseases, Department of Internal Medicine, Naval Medical Center, San Diego, California, (2) Division of Microbiology, Department of Laboratory Medicine, Naval Medical Center, San Diego, California, (3) Naval Special Warfare Center, Naval Amphibious Base Coronado, California, (4) Navy Environmental and Preventive Medicine Unit FIVE, San Diego, California, (5) Department of Pulmonary and Critical Care Medicine, Naval Medical Center, San Diego, California

## Background

- *Shewanella algae* is a motile Gram-negative bacillus
- *S. algae* is a ubiquitous marine microorganism that is an uncommon cause of human disease.
- Naval Special Warfare (NSW) trainees undergo unique physiologic stresses that include prolonged immersion in marine water, most notably during a continuous five-day operational exercise on land and sea with minimal sleep, arduous conditions including poor sanitation and hygiene (“Hell Week”).
- NSW trainees may be uniquely vulnerable to disease from this pathogen.
- We describe the clinical syndromes and outcomes of *Shewanella* infection in NSW trainees.

## Methods

- We retrospectively reviewed all cases of *Shewanella* spp. infections at Naval Medical Center San Diego between 2012-2015.

## Results

- Five patients were identified with clinical cultures demonstrating *Shewanella algae* consisting of one positive blood culture and five unique wound cultures.
- All isolates were sensitive to ceftriaxone, levofloxacin, piperacillin/tazobactam, trimethoprim-sulfamethoxazole and meropenem.
- The patients were all male between the ages of 21 to 26. (Table 1)
- All of the patients had no prior comorbidities and were otherwise healthy prior to starting NSW training.
- Four of the five patients had recently completed Hell Week, and all four presented with skin and soft tissue infections (SSTI). (Table 1)
- Two of the four patients with SSTI had concomitant bacteremia: one patient with cellulitis and *Shewanella* bacteremia, and another patient with a polymicrobial lower extremity necrotizing fasciitis and septic shock, with *Shewanella* and *Vibrio harveyi* in the wound and *V. harveyi* bacteremia. The fifth patient presented after a ruptured tympanic membrane following an eighteen-foot dive and subsequently developed otitis media. (Table 1)
- All patients responded to debridement, if appropriate, and systemic antimicrobial therapy. (Table 1)

Case	Gender /Age	Clinical Presentation	Treatment
1	26/M	<ul style="list-style-type: none"> <li>• Polymicrobial, including <i>S. algae</i>, bilateral lower extremity SSTI and acute focal bacterial nephritis</li> <li>• <i>S. algae</i> bacteremia</li> </ul>	<ul style="list-style-type: none"> <li>• Completed 14 days initially with piperacillin/tazobactam and finished with levofloxacin</li> </ul>
2	26/M	<ul style="list-style-type: none"> <li>• Left lower extremity <i>Vibrio harveyi</i> and <i>S. algae</i> necrotizing faciitis</li> <li>• <i>Vibrio harveyi</i> bacteremia</li> </ul>	<ul style="list-style-type: none"> <li>• Wide excisional debridement with split thickness skin graft left lower extremities</li> <li>• Completed three weeks of ceftazidime</li> </ul>
3	22/M	<ul style="list-style-type: none"> <li>• Multiple right pre-tibia <i>S. aureus</i> and <i>S. algae</i> abscesses</li> </ul>	<ul style="list-style-type: none"> <li>• Incision and drainage with wound vac</li> <li>• Completed 14 days initially with cefazolin plus and then finished with clindamycin</li> </ul>
4	21/M	<ul style="list-style-type: none"> <li>• Polymicrobial, including <i>S. algae</i>, bilateral lower extremity SSTI</li> </ul>	<ul style="list-style-type: none"> <li>• Local wound care</li> <li>• Completed 10 days parental and then finished with oral dicloxacillin</li> </ul>
5	21/M	<ul style="list-style-type: none"> <li>• <i>S. algae</i> and <i>P. aeruginosa</i> otitis media following a ruptured right tympanic membrane</li> </ul>	<ul style="list-style-type: none"> <li>• Completed 14 days of oral ciprofloxacin</li> </ul>

Table 1. Case characteristics

## Discussion

- *Shewanella algae* may cause invasive and potentially life-threatening infection in immunocompetent hosts
- Such invasive infections occur in otherwise-healthy NSW trainees in the setting of prolonged physiologic stress.
- Active surveillance is ongoing to monitor for *Shewanella* spp. infections in this population.
- Mitigation strategies are needed to minimize the risk of disease from rare pathogens in demanding military environments.

## References

1. Adams N, Johnson MD, Storm DW, Maves RC. Acute focal bacterial nephritis due to methicillin-resistant *Staphylococcus aureus* in an immunocompetent adult. *Infection* **2014**;42:433-6.
2. Basir N, Yong AM, Chong VH. *Shewanella putrefaciens*, a rare cause of splenic abscess. *J Microbiol Immunol Infect* **2012**;45:151-3.
3. Cheng CH, Tsau YK, Lin TY. Effective duration of antimicrobial therapy for the treatment of acute lobar nephronia. *Pediatrics* **2006**;117:e84-9.
4. Conley SP, Frumkin K. Acute lobar nephronia: a case report and literature review. *J Emerg Med* **2014**;46:624-6.
5. Diaz JH. Emerging causes of superficial and invasive infections following marine injuries and exposures. *J La State Med Soc* **2014**;166:103-8.
6. Diaz JH. Skin and soft tissue infections following marine injuries and exposures in travelers. *J Travel Med* **2014**;21:207-13.
7. Finkelstein R, Oren I. Soft tissue infections caused by marine bacterial pathogens: epidemiology, diagnosis, and management. *Curr Infect Dis Rep* **2011**;13:470-7.
8. Holt HM, Gahrn-Hansen B, Bruun B. *Shewanella algae* and *Shewanella putrefaciens*: clinical and microbiological characteristics. *Clin Microbiol Infect* **2005**;11:347-52.
9. Jacob-Kokura S, Chan CY, Kaplan L. Bacteremia and empyema caused by *Shewanella algae* in a trauma patient. *Ann Pharmacother* **2014**;48:128-36.
10. Kim DM, Kang CI, Lee CS, et al. Treatment failure due to emergence of resistance to carbapenem during therapy for *Shewanella algae* bacteremia. *J Clin Microbiol* **2006**;44:1172-4.
11. Seidel T, Kuwertz-Broking E, Kaczmarek S, et al. Acute focal bacterial nephritis in 25 children. *Pediatr Nephrol* **2007**;22:1897-901.
12. Shimizu M, Katayama K, Kato E, Miyayama S, Sugata T, Ohta K. Evolution of acute focal bacterial nephritis into a renal abscess. *Pediatr Nephrol* **2005**;20:93-5.
13. Tsai MS, You HL, Tang YF, Liu JW. *Shewanella* soft tissue infection: case report and literature review. *Int J Infect Dis* **2008**;12:e119-24.
14. Vignier N, Barreau M, Olive C, et al. Human infection with *Shewanella putrefaciens* and *S. algae*: report of 16 cases in Martinique and review of the literature. *Am J Trop Med Hyg* **2013**;89:151-6.